Bluejay Diagnostics, Inc.
BJDXNASDAQHealthcareMedical - Devices
Previous close
$0.9109
−$0.0284 · -3.02%
BJDX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
45
Fair Value
Momentum
19
Strong Down
Sentiment
56
Mixed
Risk resilience
33
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Indranil Dey
- Listed since
- Nov 10, 2021
- Employees
- 6
Market position
Day range
Current $0.9109
52-week range
Current $0.9109
- Open
- $0.9259
- Previous close
- $0.9393
- Volume
- 120.32K
- 0.03× average
- Average volume
- 3.84M
- Average daily volume
- Market cap
- 942.52K USD
- Beta
- 0.89
- Market reference 1
- 50-day average
- $1.7813
- -48.86% below average
- 200-day average
- $2.7251
- -66.57% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -3.85M USD
- P/E (TTM)
- -0.08×
- P/B (TTM)
- 0.2×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.58×
- Earnings yield
- -571.21%
- Free cash flow yield
- -519.40%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -114.61%
- Return on assets
- -96.20%
- Return on invested capital
- -113.98%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 4.88×
- Altman Z-score
- -6.57
- Piotroski F-score
- 3 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 249.04K USD | — |
| Cost of goods sold | — | — | — | 200.13K USD | — |
| Gross profit | — | — | — | 48.91K USD | — |
| Research and development | 3.05M USD | 3.47M USD | 5.71M USD | 4.15M USD | 1.15M USD |
| Selling, general, and administrative | 3.91M USD | 3.7M USD | 4.6M USD | 5.21M USD | 2.08M USD |
| Operating expenses | 6.95M USD | 7.17M USD | 10.31M USD | 9.37M USD | 3.23M USD |
| Interest income | 97.56K USD | 145.82K USD | 164.9K USD | 89.67K USD | 513.3K USD |
| Interest expense | 839 USD | 823.03K USD | — | — | 367.46K USD |
| Depreciation and amortization | 170.68K USD | 199.1K USD | 780.96K USD | 306.37K USD | 145.72K USD |
| Operating income | −6.95M USD | −7.17M USD | −10.31M USD | −9.32M USD | −3.23M USD |
| Net income | −6.85M USD | −7.72M USD | −9.95M USD | −9.3M USD | −3.73M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 63%
- 5 beats, 3 misses, 0 met estimates
- Average EPS surprise
- -52374.53%
- 8 comparable reports
- Latest EPS result
- -1.12
- Estimate -3,520 · Beat by 99.97%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
BJDX news
BJDX peers
Continue in GoAI
Research BJDXresearch.disclaimer